Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections. One limitation to the evaluation of potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack of susceptible small animals in large numbers. Commercially available laboratory strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors. Here, we transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues. hACE2-transduced mice were productively infected with SARS-CoV-2, and this resulted in high viral titers in the lung, lung pathology, and weight loss. Passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss. The development of an accessible mouse model of SARS-CoV-2 infection and pathogenesis will expedite the testing and deployment of therapeutics and vaccines. Graphical Abstract Highlights • Adenovirus transduction of human ACE2 enables SARS-CoV-2 infection of BALB/c mice • High levels of viral RNA and infectious SARS-CoV-2 accumulate in lungs • Mice transduced with human ACE2 develop viral pneumonia after SARS-CoV-2 infection • Neutralizing mAbs protect from SARS-CoV-2-induced lung infection and inflammation Laboratory mice transduced with adenoviruses encoding human ACE2 are permissive for SARS-CoV-2 and develop pneumonia. Passive transfer of a neutralizing monoclonal antibody reduces lung infection, inflammation, and disease.
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, coronavirus, Pathogenesis, Pneumonia, antibody, animal model, mice,